# Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC)

> **NCT06551233** · PHASE1 · RECRUITING · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 30 (estimated)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** 9MW2821

## Key facts

- **NCT ID:** NCT06551233
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-22
- **Primary completion:** 2024-11-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06551233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06551233, "Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06551233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*